国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (6): 366-369.doi: 10.3760/cma.j.issn.1673-422X.2019.06.011

• 综述 • 上一篇    下一篇

DLL3在小细胞肺癌中的表达及其在靶向治疗中的应用

左昊,李娜,陈罗军,刘华丽,宋启斌   

  1. 武汉大学人民医院肿瘤中心430060
  • 出版日期:2019-06-08 发布日期:2019-07-11
  • 通讯作者: 宋启斌，Email: qibinsong@163.com E-mail:qibinsong@163.com
  • 基金资助:

    国家自然科学基金（81802980）

Expression of DLL3 in small cell lung cancer and its application in targeted therapy

Zuo Hao, Li Na, Chen Luojun, Liu Huali, Song Qibin   

  1. Cancer Center of Renmin Hospital of Wuhan University, Wuhan 430060, China
  • Online:2019-06-08 Published:2019-07-11
  • Contact: Song Qibin, Email: qibinsong@163.com E-mail:qibinsong@163.com
  • Supported by:

    National Natural Science Foundation of China (81802980)

PDF

868

摘要： 小细胞肺癌（SCLC）生物学行为恶劣，复发转移概率高，治疗手段有限。Notch信号传导通路是一种进化保守途径，可通过局部细胞细胞相互作用来调控多种类型细胞的生长，其可调控细胞的分化、增殖和存活。Delta样蛋白3(DLL3)作为Notch通路的配体，特异性高表达于SCLC细胞表面。DLL3在SCLC的肿瘤启动和上皮间质转化、侵袭和转移中扮演着重要的角色。Rovalpituzumab tesirine是一种靶向DLL3抗体的药物偶联物，在SCLC治疗方面具有巨大的潜力。

关键词: 小细胞肺癌, 受体, Notch, Delta样蛋白3

Abstract: Small cell lung cancer (SCLC) has a poor biological behavior, high probability of recurrence and metastasis, and limited treatment. The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cellcell interactions. It controls the differentiation, proliferation and survival of cells. As a ligand for the Notch pathway, deltalike protein 3 (DLL3) is highly expressed on the membrane of SCLC cells. DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition, invasion and metastasis of SCLC. Rovalpituzumab tesirine is a conjugate of directed against DLL3, which shows great potential for SCLC therapy.

Key words: Small cell lung carcinoma, Receptors, Notch, Delta-like protein 3